Profund Advisors’s Celldex Therapeutics CLDX Stock Holding History

Profund Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Sell	28,930 -596	-2%	-$19.3K	0.03%	332
2026 Q1	$937K	Sell	29,526 -12,928	-30%	-$352K	0.03%	363
2025 Q4	$1.15M	Buy	42,454 +21,149	+99%	+$557K	0.04%	320
2025 Q3	$551K	Buy	21,305 +5,880	+38%	+$136K	0.02%	482
2025 Q2	$314K	Sell	15,425 -7,220	-32%	-$141K	0.01%	665
2025 Q1	$411K	Sell	22,645 -6,789	-23%	-$152K	0.02%	544
2024 Q4	$744K	Buy	29,434 +10,873	+59%	+$295K	0.03%	362
2024 Q3	$631K	Sell	18,561 -3,945	-18%	-$150K	0.02%	444
2024 Q2	$833K	Sell	22,506 -7,841	-26%	-$296K	0.03%	351
2024 Q1	$1.27M	Buy	30,347 +5,861	+24%	+$241K	0.05%	296
2023 Q4	$971K	Sell	24,486 -3,553	-13%	-$105K	0.04%	331
2023 Q3	$772K	Sell	28,039 -9,382	-25%	-$294K	0.04%	345
2023 Q2	$1.27M	Buy	37,421 +10,049	+37%	+$339K	0.07%	263
2023 Q1	$985K	Buy	+27,372	New	+$1.18M	0.06%	305

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's CLDX Position: Q2 2026 in Review

Profund Advisors reduced its Celldex Therapeutics (CLDX) stake by 2% in Q2 2026, selling an estimated $19.3K and leaving 28,930 shares worth $1.08M. The position accounts for 0.03% of the portfolio, ranked #332.

Profund Advisors first reported a position in CLDX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.27M in Q1 2024. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Profund Advisors held 28,930 shares of Celldex Therapeutics worth $1.08M as of Q2 2026.
Profund Advisors sold 596 Celldex Therapeutics shares in Q2 2026, an estimated $19.3K.
Celldex Therapeutics made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #332 holding.
Profund Advisors first reported a position in Celldex Therapeutics in Q1 2023 and has held it in 14 quarters since.
Profund Advisors's Celldex Therapeutics position peaked at $1.27M in Q1 2024.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.